TherapeuticsMD (TXMD) Total Non-Current Liabilities (2012 - 2026)

TherapeuticsMD has reported Total Non-Current Liabilities for 11 years, with the latest figure at $9.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 9.03% year-over-year to $9.7 million; the trailing twelve-month figure through Mar 2026 stood at $9.7 million (down 9.03% YoY), and the FY2025 full-year result was $9.9 million, down 7.48% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $9.7 million, down from $9.9 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $272.7 million in Q1 2022, with the low at $9.7 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $50.6 million across 5 years, with a median of $12.8 million in 2024.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities sank 90.29% — and 2025, when it decreased 7.48%.
• TherapeuticsMD's Total Non-Current Liabilities stood at $54.2 million in 2022, then slumped by 75.31% to $13.4 million in 2023, then decreased by 20.01% to $10.7 million in 2024, then slipped by 7.48% to $9.9 million in 2025, then slipped by 1.74% to $9.7 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $9.7 million (Q1 2026), $9.9 million (Q4 2025), and $10.4 million (Q3 2025), per Business Quant data.